Tests donor-derived CAR T cells against CD19 leukemia in young patients
Tests donor CAR T cells targeting CD19 in young people with relapsed leukemia.
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Memphis, United StatesSee the site
- Trial code
- Registry title
- Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 60 people, planned
- Started
- 14 Feb 2024
- Expected to end
- 1 Jul 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- CD19-CAR(Mem) T-cells
- Cyclophosphamide
- Fludarabine
- Mesna
- CliniMACS
- Leukapheresis
- Record updated
- 31 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults up to 21 years old whose CD19-positive leukemia has come back or has not responded to treatment. They get donor-made CAR T-cells.
- Age
- Up to 21 years old
- Sex
- All sexes can join
- Disease stage
- Relapsed or refractory CD19-positive leukemia, with leukemia detectable in the bone marrow. Examples: second or later relapse, any relapse after a donor stem-cell transplant, or no response after at least 2 cycles of intensive chemotherapy or after salvage therapy.
- Earlier treatment
- If there was a donor stem-cell transplant, at least 3 months must have passed, with no active graft-versus-host disease in the last 2 months. No donor lymphocyte infusion in the 28 days before the infusion. Cohort B patients cannot use their own CAR T-cells, for example after earlier CAR T-cell therapy failed.
- Biomarker or test result
- The leukemia must be CD19-positive, confirmed within 2 months and after any CD19-directed therapy.
Main reasons for not taking part
- CNS-3 disease, or any leukemia in the brain or spinal fluid with neurologic symptoms
- History of HIV infection
- Severe uncontrolled bacterial, viral or fungal infection
- Pregnant, or breastfeeding
- History of allergic reaction to products containing mouse protein
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- Age ≥ 18 years old
- At least single haplotype matched (≥ 3/6) family member
- HIV negative
- For females of child bearing age: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND Not lactating with intent to breastfeed
- Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance. *For Cohort A only, an ineligible donor may be used under urgent medical need if the reason for ineligibility was previously present at time of transplant determination; For Cohort A only, identified recipient with relapsed and/or refractory CD19-positive leukemia; For Cohort B only, iIdentified recipient with relapsed and/or refractory CD19-positive leukemia who is not suitable to receive autologous CD19-CAR T-cell therapy as defined by the following:
- Relapsed and/or refractory disease despite prior treatment with autologous CD19- CAR T-cell therapy
- History of prior autologous leukapheresis failure
- History of prior autologous CAR T-cell manufacturing failure
- Unable to undergo autologous leukapheresis in the opinion of the study PI(s): examples may include - patient small size/low weight, inadequate T-cell counts, rapidly progressive leukemia, clinical status not amenable to apheresis; Eligibility Criteria for Patients: Pre-Treatment Evaluation*; Inclusion
- MEMCAR19 recipient candidate ≤<21 years old with rRelapsed and/or refractory CD19-positive leukemia; *Due to potential scheduling challenges, all recipients may not be offered the Pre-Treatment Evaluation consent. This will not be counted as a deviation; Eligibility Criteria for Patients:Treatment
- Age ≤ 21 years old
- Relapsed and/or refractory CD19-positive leukemia*:; Refractory disease (defined as any of the following):; Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission; Refractory disease despite salvage therapy; Relapsed disease (defined as any of the following):; 2nd or greater relapse; Any relapse after allogeneic hematopoietic cell transplantation (HCT); 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT; CD19-positivity confirmed within 2 months and after receipt of any CD19-directed therapy
- Patient cohorts:; Cohort A: patient has previously received a HCT from the selected CAR T-cell donor; Cohort B - patient has NOT previously received a HCT from the selected CAR T-cell donor
- For Cohort B only, not suitable to receive autologous CD19-CAR T-cell therapy as defined above in Criteria: Eligibility Criteria for Donors: Apheresis and Manufacturing
- Detectable medullary CD19-positive leukemia
- Estimated life expectancy of ≥ 8 weeks
- Karnofsky or Lansky performance score ≥ 50
- No CNS-3 disease or any level of detectable leukemia in CNS with associated neurologic symptoms
- If history of allogeneic HCT (regardless of donor type), prior to planned CAR T-cell infusion, must meet the following criteria:; ≥ 3 months from HCT; have recovered from prior HCT therapy; have no evidence of active GVHD within prior 2 months; have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned CAR T-cell infusion
- Adequate cardiac function: left ventricular ejection fraction ≥ 40% or shortening fraction ≥ 25% (function may be supported by pharmacologic therapy)
- EKG without evidence of clinically significant arrhythmia
- Adequate renal function: creatinine clearance or radioisotope GFR 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if < 2 years of age)
- Adequate pulmonary function: forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing
- Total bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age
- No history of HIV infection
- No evidence of severe, uncontrolled bacterial, viral or fungal infection
- Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
- For females of child bearing age:; Not pregnant with negative serum or urine pregnancy test ≤ 7 days prior to enrollment AND Not lactating with intent to breastfeed
- If sexually active, agreement to use birth control until 6 months after CAR T-cell infusion
- No history of hypersensitivity reactions to murine protein-containing products
- Not receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone ≤ 7 days prior to CAR T-cell infusion
- Not receiving systemic therapy ≤ 14 days prior to CAR T-cell infusion, which will interfere with the activity of the CAR T-cell product in vivo (in the opinion of the study PI(s))
- Not receiving intrathecal chemotherapy ≤ 7 days prior to CAR T-cell infusion
Who cannot take part
- NA
Where in United States
- St. Jude Children's Research HospitalMemphis, United StatesContact: Aimee C. Talleur, MDTaking people
About the trial
What the trial wants to find out
This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients ≤ 21 years old with relapsed and/ or refractory CD19-positive leukemia.
Read full original descriptionShow less
Primary Objective
To determine the maximum tolerated dose (MTD) and characterize the safety profile and dose-limiting toxicities (DLTs) of treatment with allogeneic CD19-CAR.CD45RA-negative T-cells in pediatric, adolescent and young adult patients ≤ 21 years of age, with relapsed and/or refractory CD19-positive leukemia.
Secondary Objectives
* To evaluate the anti-leukemic activity of allogeneic CD19-CAR.CD45RA-negative T-cells. * To determine rates and severity of graft-versus-host-disease (GVHD) after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells.
Exploratory Objectives
* To study the expansion, persistence and phenotype of allogeneic CD19-CAR.CD45RA-negative T-cells. * To characterize the cytokine profile in the peripheral blood and CSF after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells. * To assess whether allogeneic CD19-CAR.CD45RA-negative T-cells acquire functional versus exhaustion-associated epigenetic programs. * To determine immune reconstitution post treatment, and the clonal structure and endogenous repertoire of allogeneic CD19-CAR.CD45RA-negative T-cells and relate inferred specificity to CAR response profiles. * To characterize incidence and mechanisms of relapse post-therapy with allogeneic CD19-CAR.CD45RA-negative T-cells.
The 2 groups in the trial
- Group ATreatment being tested
Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.
Treatment: CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine, Mesna, CliniMACS, and Leukapheresis
- Group BTreatment being tested
Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.
Treatment: CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine, Mesna, CliniMACS, and Leukapheresis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia
- Plain-language title
- Tests donor-derived CAR T cells against CD19 leukemia in young patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 31 August 2026